The cell technologies in modification of mesh materials used in urology


DOI: https://dx.doi.org/10.18565/urology.2021.2.94-99

I.V. Maiborodin, G.YU. Yarin, I.A. Vilgelmi, S.V. Marchukov, V.I. Maiborodina, N.V. Onoprienko

1) Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, Novosibirsk, Russia; 2) Institute of Molecular Pathology and Pathomorphology, Federal State Budget Scientific Institution “Federal Research Center of Fundamental and Translational Medicine”, Novosibirsk, Russia
Based on the literary analysis, the influence of cellular technologies on the results of implantation of mesh materials was studied. The scientific literature of recent years contains a large amount of data devoted to the study of mesh structures and the possibilities of their modification using multipotent stromal cells (MSC) for implantation into patients for correcting tissue defects and pelvic organ prolapse. However, the ideal implant has not yet been created. Additional studies with a longer follow-up period are needed to determine the most successful and safe methods and materials for the restoration of pathologically altered or lost tissues and the transition to clinical trials. It is also yet to come to an unambiguous understanding of the best sources of MSC, ways for stimulation of proliferation, preservation and delivery of these cells into the necessary tissues of the body, to thoroughly study the causes of inefficiency and the risks of developing various complications, especially in the long term. The progress of urological implantology in modern conditions, of course, will be associated with the introduction of modern materials and technologies, including the using MSC.
Keywords: meshes, multipotent stromal cells, implantation, cell therapy, complications
Read entire article

About the Autors

Corresponding author: I.V. Maiborodin – MD, Ph.D., DrSc(Med), Professor, Chief Researcher, Laboratory of Health Management Technologies, The Center of New Medical Technologies, Institute of Chemical Biology and Fundamental Medicine, The Russian Academy of Sciences, Siberian Branch, Novosibirsk, Russia; Chief Researcher, Laboratory of cell biology and cytology, Institute of Molecular Pathology and Pathomorphology, Federal State Budgetary Scientific Institution «Federal Research Center for Fundamental and Translational Medicine» of the Ministry of Science and Higher Education of the Russian Federation, Novosibirsk, Russia; e-mail: imai@mai.ru


Similar Articles

Back to Content

Бионика Медиа